$24.25
7.99% today
NYSE, Nov 04, 08:46 pm CET
ISIN
US3580291066
Symbol
FMS

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock price

$26.35
-0.40 1.50% 1M
+0.73 2.85% 6M
+3.71 16.39% YTD
+6.30 31.42% 1Y
+12.50 90.25% 3Y
-12.53 32.23% 5Y
-18.55 41.31% 10Y
+18.53 236.74% 20Y
NYSE, Closing price Mon, Nov 03 2025
-0.49 1.83%

New AI Insights on Fresenius Medical Care AG & Co. KGaA Sponsored ADR Insights AI Insights on Fresenius Medical Care AG & Co. KGaA Sponsored ADR

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$15.6b
Enterprise Value
$25.8b
Net debt
$10.2b
Cash
$2.5b
Shares outstanding
293.4m
Valuation (TTM | estimate)
P/E
10.2 | 6.0
P/S
0.7 | 0.7
EV/Sales
1.2 | 1.1
EV/FCF
11.1
P/B
1.0
Dividends
DPS
$0.81
Yield 1Y | 5Y
3.1% | 2.8%
Growth 1Y | 5Y
26.8% | 2.6%
Payout 1Y | 3Y
30.5% | 29.1%
Increased
2 Years
Financials (TTM | estimate)
Revenue
$22.5b | $22.7b
EBITDA
$3.5b | $4.1b
EBIT
$1.6b | $2.4b
Net Income
$756.3m | $1.3b
Free Cash Flow
$2.3b
Growth (TTM | estimate)
Revenue
0.5% | 1.8%
EBITDA
-4.1% | 19.3%
EBIT
2.7% | 63.4%
Net Income
23.8% | 108.8%
Free Cash Flow
50.2%
Margin (TTM | estimate)
Gross
24.7%
EBITDA
15.4% | 18.2%
EBIT
7.2%
Net
3.4% | 5.7%
Free Cash Flow
10.3%
Financial Health
Equity Ratio
43.4%
Return on Equity
3.7%
ROCE
5.4%
ROIC
4.1%
Debt/Equity
0.8
More
EPS
$2.6
FCF per Share
$7.9
Short interest
0.2%
Employees
112k
Rev per Employee
$200.0k
Show more

Is Fresenius Medical Care AG & Co. KGaA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

10x Buy
40%
9x Hold
36%
6x Sell
24%

Analyst Opinions

25 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

Buy
40%
Hold
36%
Sell
24%

Financial data from Fresenius Medical Care AG & Co. KGaA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
22,487 22,487
1% 1%
100%
- Direct Costs 16,940 16,940
1% 1%
75%
5,547 5,547
2% 2%
25%
- Selling and Administrative Expenses 3,616 3,616
1% 1%
16%
- Research and Development Expense 198 198
19% 19%
1%
3,465 3,465
4% 4%
15%
- Depreciation and Amortization 1,858 1,858
9% 9%
8%
EBIT (Operating Income) EBIT 1,608 1,608
3% 3%
7%
Net Profit 756 756
24% 24%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Fresenius Medical Care AG & Co. KGaA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Neutral
PRNewsWire
about 8 hours ago
Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7% Reported operating income grew by 3%, reported net income3 by 29% Net leverage ratio further improved to 2.6x, in parallel to sh...
Positive
Reuters
about 14 hours ago
Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take hold.
Neutral
PRNewsWire
5 days ago
Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation highlights the association between HDF and reduced risk of cardiovascular and fluid-related hospitalization outcomes.
More Fresenius Medical Care AG & Co. KGaA Sponsored ADR News

Company Profile

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Head office Germany
CEO Helen Giza
Employees 111,513
Founded 1996
Website www.freseniusmedicalcare.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today